Item 8.01. Other Events.

On March 3, 2023, Bellerophon Therapeutics, Inc. (the "Company") suspended, and is not offering any shares of its common stock pursuant to, the prospectus supplement dated January 19, 2023 relating to the Open Market Sale Agreement, dated as of July 17, 2020 (the "Sales Agreement"), by and between the Company and Jefferies LLC. The Company will not make any sales of common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the SEC; however, the Sales Agreement remains in full force and effect.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, which is being made only by means of a written prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction..


                                       2

© Edgar Online, source Glimpses